Table 3.
Procedure characteristics of the study and the control groups
| Characteristic | Study group | Control group | p value |
|---|---|---|---|
| Sequence no. of procedure | 0.62 | ||
| 1 | 25 (48) | 11 (42) | |
| 2 | 14 (27) | 7 (27) | |
| 3 | 5 (10) | 3 (12) | |
| > 3 | 8 (15) | 5 (19) | |
| Type of TACE | |||
| Conventional TACE | 29 (56) | 19 (73) | |
| Drug-eluting beads TACE | 23 (44) | 7 (27) | |
| Selectivity of TACE | |||
| Lobar | 11 (21) | 4 (15) | |
| Selective | 16 (31) | 10 (38) | |
| Superselective | 25 (48) | 12 (46) | |
| Catheter positions for drug delivery | 0.69 | ||
| 1 | 40 (77) | 19 (73) | |
| 2 | 12 (23) | 7 (27) | |
| DF time (min)a | 15.6; 9.8 (5.6–37.2) | 15.5; 11.0 (8.6–54.6) | 0.34 |
| No. of DSA acquisitionsa | 6; 3.8 (3–11) | 6; 3.0 (3–13) | 0.97 |
| DSA time (s)a | 71.5; 48.0 (17.4–167.4) | 63.9; 35.3 (24.4–204.2) | 0.66 |
| No. of CBCT acquisitionsa | 3; 2 (0–5) | 3; 1 (0–6) | 0.56 |
Except where indicated, data represent numbers of patients and numbers in parentheses are percentages
aData represented as median; interquartile range (range)